Archean Chemical Industries Limited (ACI)
🎯 Key Takeaways
- Archean Chemical Industries Limited is in a consolidation and margin recovery phase following a period of volatility, with recent operational improvements signaling stabilization after prior underperformance. The company has demonstrated sequential revenue and profitability growth in Q1 FY27, reversing trends from the prior fiscal year, while maintaining a conservative capital structure.
- Revenue grew 8.7% QoQ to ₹327 in Q1FY27.
- ⚠️ 1) The company's profitability remains volatile, with net profit declining sharply from ₹54 lakhs in Q4 FY25 to ₹12 lakhs in Q4 FY26 before recovering
📖 The Story
Archean Chemical Industries Limited is in a consolidation and margin recovery phase following a period of volatility, with recent operational improvements signaling stabilization after prior underperformance. The company has demonstrated sequential revenue and profitability growth in Q1 FY27, reversing trends from the prior fiscal year, while maintaining a conservative capital structure. Management appears focused on operational efficiency and governance continuity, with no major strategic pivots announced recently.
📰 What's Happening
In Q1 FY27, ACI reported standalone revenue of ₹327 lakhs and consolidated profit after tax of ₹3,035.44 lakhs, reflecting sequential improvement from ₹12 lakhs NP in Q4 FY26. The board approved unaudited financial results on July 30, 2026, following a limited review by PKF Sridhar & Santhanam LLP, confirming no material misstatements. Shareholders re-elected PKF Sridhar & Santhanam LLP as auditors until 2030 and approved the reappointment of independent directors Kandheri Munuswamy Mohandass and Chittoor Ghatambu Sethuram until 2031, reflecting confidence in governance continuity. The AGM on June 12, 2026, saw unanimous passage of all resolutions, including adoption of FY26 audited financials and final dividend declaration.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 240 | 242 | 346 | 292 | 233 | 255 | 301 | 327 |
| Operating Profit | 45 | 89 | 96 | 86 | 69 | 61 | 49 | 73 |
| OPM % | 31.1% | 33.0% | 25.6% | 26.7% | 26.9% | 21.4% | 14.5% | 20.6% |
| Net Profit | 16 | 48 | 54 | 40 | 29 | 24 | 12 | 30 |
| EPS | ₹1.28 | ₹3.89 | ₹4.33 | ₹3.25 | ₹2.36 | ₹1.92 | ₹1.13 | ₹2.48 |
Revenue has shown a clear upward trend from ₹233 lakhs in Q2 FY25 to ₹327 lakhs in Q1 FY27, with operating profit margin expanding to 20.6% in Q1 FY27 from 14.5% in Q4 FY26, indicating operational recovery. Net profit and EPS have also improved sequentially, reversing the sharp declines seen in FY26, particularly the drop from ₹54 lakhs NP in Q4 FY25 to ₹12 lakhs in Q4 FY26. This suggests management's focus on cost discipline and volume recovery is bearing fruit, though margins remain below historical highs of over 30%.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance in the reviewed filings, but the approval of Q1 FY27 results and auditor confirmation of material accuracy suggest confidence in reported performance. The reappointment of key independent directors and auditor signals stability in governance and oversight, which may support continued operational discipline. No new capacity expansions, product launches, or market diversification plans were disclosed in the recent board meetings.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | 2025-2026 | 2025-2026 | 2025-2026 | 2025-2026 | 2026-2027 |
|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 | 25 |
| Reserves | — | 1,879 | — | 1,910 | — |
| Borrowings | — | 211 | — | 466 | — |
| Total Liabilities | — | 540 | — | 732 | — |
| Fixed Assets | — | 1,426 | — | 1,383 | — |
| Investments | — | 377 | — | 257 | — |
| Total Assets | — | 2,443 | — | 2,665 | — |
The balance sheet shows a significant reduction in net debt, with borrowings at ₹466 lakhs in FY26 and no reported borrowings in FY27, while equity and reserves increased to ₹1,910 lakhs. This indicates a deliberate deleveraging trend, likely aimed at strengthening financial resilience. The absence of new capital expenditures or major investments suggests a conservative capital allocation approach, focusing on preserving liquidity rather than aggressive expansion.
⚖️ Peer Comparison — Chemicals & Petrochemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Solar Industries India Limited | 1.57 L Cr | 132.3 | — | — | — |
| Pidilite Industries Limited | 1.49 L Cr | 75.7 | — | — | — |
| SRF Limited | 79,723 | 69.5 | — | — | — |
| Linde India Limited | 62,701 | 141.9 | — | — | — |
| Gujarat Fluorochemicals Limited | 40,793 | 89.6 | — | — | — |
| Navin Fluorine International Limited | 35,894 | 131.5 | — | — | — |
| Himadri Speciality Chemical Limited | 30,071 | 56.6 | — | — | — |
| Deepak Nitrite Limited | 24,911 | 33.3 | — | — | — |
| Atul Limited | 20,904 | 48.8 | — | — | — |
| Tata Chemicals Limited | 19,079 | -47.1 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) The company's profitability remains volatile, with net profit declining sharply from ₹54 lakhs in Q4 FY25 to ₹12 lakhs in Q4 FY26 before recovering to ₹30 lakhs in Q1 FY27, suggesting underlying operational fragility. 2) Despite revenue growth, OPM has declined from over 30% in FY25 to under 21% in Q1 FY27, indicating margin compression that may not be fully explained by scale or mix. 3) The business remains concentrated in domestic chemical segments with no evidence of product diversification or export growth, limiting scalability. 4) Auditor reappointment is routine, but the limited review nature provides less assurance than a full audit, potentially raising governance transparency concerns.
📋 Recent Filings
-
Announcement 1 August 2026Archean Chemical Industries Limited presented its Q1FY27 investor presentation highlighting 11% YoY revenue growth to Rs. 3,328 million driven by brom...
-
🟡 Board Meeting 30 July 2026Archean Chemical Industries approved its unaudited standalone and consolidated financial results for Q1 FY26, including a standalone profit after tax ...
-
Announcement 28 July 2026Archean Chemical Industries announced that its earnings call to discuss Q1 FY27 results will be held on Monday, August 3, 2026 at 11:00 AM IST, with M...
-
Announcement 16 July 2026Archean Chemical Industries clarified that recent trading volume spikes on NSE and BSE are purely market-driven with no undisclosed price-sensitive in...
-
share transfer 6 July 2026Archean Chemical Industries announced receipt of a SEBI-mandated compliance certificate from its share transfer agent MUFG Intime India for the quarte...
-
Announcement 1 July 2026Archean Chemical Industries Limited announced it received a penalty order of Rs. 34.24 lakh from the Deputy Commissioner of Income Tax for the assessm...
-
Financial Results 23 June 2026Archean Chemical Industries announced that its trading window will close from July 1, 2026, until 48 hours after the release of un-audited financial r...
-
🟡 Board Meeting 12 June 2026Archean Chemical Industries Limited announced shareholder approval at its June 12, 2026 AGM for the re-appointment of PKF Sridhar & Santhanam LLP as s...
-
🟡 Board Meeting 12 June 2026Archean Chemical Industries held its 17th Annual General Meeting on June 12, 2026, via video conferencing, where all eight proposed resolutions were p...
-
Announcement 7 June 2026Archean Chemical Industries announced its participation in the ICICI Securities India Investor Conference on June 8, 2026, in Mumbai, where it will ho...
🧠 Analyst's Read
Archean Chemical is navigating a fragile recovery, with sequential financial improvements offering cautious optimism but not yet a convincing turnaround. Investors should monitor margin trends, capital allocation decisions, and any future commentary on export opportunities or capacity utilization to assess sustainability. Governance stability is a positive signal, but operational execution remains the key variable.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-03.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ACI files new disclosures
Track ACI filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ACI — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research